TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11699398

Group type: EXPERIMENTAL
Intervention: Early outpatient supportive care following induction chemotherapy with cytosine arabinoside and an anthracycline.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Inpatient care (control group).
Number of subjects: 19
Study: 9608962

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.25 mg.kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.25 mg.kg‐1 plus intranasal atropine 0.02 mg.kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 0.25 mg.kg‐1 plus intramuscular atropine 0.02 mg.kg‐1
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intranasal saline drops
Number of subjects: 80
Study: 8022946

Group type: EXPERIMENTAL
Intervention: 1.75% THC
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3.55% THC
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2685215

Group type: EXPERIMENTAL
Intervention: Cefaclor (CCL) for more than two weeks
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Cefaclor (CCL)
Number of subjects: 193
Study: 4758423

Group type: EXPERIMENTAL
Intervention: Practolol 200 mg by mouth at the beginning and end of each dialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haemodialysis
Number of subjects: 0
Study: 31274239

Group type: EXPERIMENTAL
Intervention: EIS + IACIT
Number of subjects: 0

Group type: COMPARATOR
Intervention: EIS only
Number of subjects: 0
Study: 30964698

Group type: EXPERIMENTAL
Intervention: Radiotherapy before surgery (RS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery followed by radiotherapy (SR)
Number of subjects: 0
Study: 28619294

Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract (MLE) 1000mg standardized, given three times daily with meals for 3 months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract (MLE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26051158

Group type: EXPERIMENTAL
Intervention: PEG marker system
Number of subjects: 55
Study: 23442287

Group type: EXPERIMENTAL
Intervention: Bioenhanced whey protein with low-volume resistance training (BWPLV)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Bioenhanced whey protein with moderate-volume resistance training (BWPMV)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Standard whey protein with moderate-volume resistance training (SWPMV)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo with moderate-volume resistance training (PLA)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control with moderate-volume resistance training (CON)
Number of subjects: 106
Study: 20934270

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation with lymph nodes examined
Number of subjects: 445
Study: 18062846

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Dexamethasone 0.1%/tobramycin 0.3% (DM/T)
Number of subjects: 276
Study: 16565634

Group type: EXPERIMENTAL
Intervention: Onsite care in the VA SUD clinic
Number of subjects: 720

Group type: COMPARATOR
Intervention: Referral care in the VA general internal medicine clinic
Number of subjects: 720
Study: 12503834

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10088561

Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 57

Group type: COMPARATOR
Intervention: Open fundoplication
Number of subjects: 57
Study: 8681311

Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg rHCNTF
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 1 microgram/kg rHCNTF
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 3 micrograms/kg rHCNTF
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 7 micrograms/kg rHCNTF
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg rHCNTF
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 30 micrograms/kg rHCNTF
Number of subjects: 57

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 57
Study: 1822833

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg chronic administration
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg acute administration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nisoldipine (5 mg or 10 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Head-up tilt
Number of subjects: 18
Study: 6798765

Group type: EXPERIMENTAL
Intervention: Preparation I (SH D 356 A) containing 75 micrograms delta 15-d-norgestrel (Gestoden) + 30 micrograms ethinyloestradiol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Preparation II (SH D 356 B) containing 75 micrograms d-norgestrel + 30 micrograms ethinyloestradiol
Number of subjects: 20
Study: 6494382

Group type: EXPERIMENTAL
Intervention: Lysine vasopressin (LVP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study: 31436181

Group type: EXPERIMENTAL
Intervention: Topical olopatadine (0.1%)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Topical bepotastine (1.5%)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Topical alcaftadine (0.25%)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 30342467

Group type: EXPERIMENTAL
Intervention: Sufentanil plus low dose of dexmedetomidine (0.02 μg/kg/h each, Group D1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sufentanil plus high dose of dexmedetomidine (0.04 μg/kg/h, Group D2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (sufentanil 0.02 μg/kg/h, Group C)
Number of subjects: 90
Study: 27329516

Group type: EXPERIMENTAL
Intervention: Pre-sleep chocolate milk (CM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-nutritive placebo (PL)
Number of subjects: 12
Study: 23856151

Group type: EXPERIMENTAL
Intervention: Strict education on clinical practice guidelines by a physical therapist and an occupational therapist
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard therapy services
Number of subjects: 37
Study: 22820898

Group type: EXPERIMENTAL
Intervention: Escitalopram 10-mg daily
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 20194854

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (arm B)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Gemcitabine alone (arm A)
Number of subjects: 400
Study: 18831882

Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoic acid (ethyl-EPA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 15699018

Group type: EXPERIMENTAL
Intervention: Continuous positive airways pressure treatment for 6 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 27
Study: 11815429

Group type: EXPERIMENTAL
Intervention: Radiofrequency pulse applied at the site with mechanical translation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Single radiofrequency pulse applied at the site with diastolic potential
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Three radiofrequency pulses delivered to the site with the earliest retroPP
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control stimulation
Number of subjects: 9
Study: 10075297

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 53

Group type: COMPARATOR
Intervention: No prophylactic antibiotics (Control)
Number of subjects: 53
Study: 7551301

Group type: EXPERIMENTAL
Intervention: 90-microF biphasic waveform
Number of subjects: 30

Group type: COMPARATOR
Intervention: 125-microF biphasic waveform
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 90-microF biphasic waveform with endocardial lead system
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 90-microF biphasic waveform with endocardial-subcutaneous array lead system
Number of subjects: 30
Study: 2123355

Group type: EXPERIMENTAL
Intervention: Mackerel supplement (135 g per day for 6 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Meat (control) paste (135 g per day for 6 weeks)
Number of subjects: 40
Study: 7362089

Group type: EXPERIMENTAL
Intervention: Terbutaline tablet (2.5, 3.75, or 5.0 mg depending on weight)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Terbutaline oral solution (2.5, 3.75, or 5.0 mg depending on weight)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (none specified)
Number of subjects: 16
Study: 30683249

Group type: EXPERIMENTAL
Intervention: Post-operative evidence based bundle/standard education
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard education packet
Number of subjects: 50
Study: 27865446

Group type: EXPERIMENTAL
Intervention: Utrogestan 100 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Utrogestan 200 mg
Number of subjects: 150
Study: 26471076

Group type: EXPERIMENTAL
Intervention: Cereal-based breakfasts and fruit products (salad and juice) consumed within breakfast or as a midmorning snack
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fruit salad consumed as a midmorning snack
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Regular consumption of breakfast and whole fruit as midmorning snack
Number of subjects: 9
Study: 23433054

Group type: EXPERIMENTAL
Intervention: Alcohol extract of Sanyak
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sanyak pharmacopuncture
Number of subjects: 0
Study: 21831003

Group type: EXPERIMENTAL
Intervention: Self-talk focusing on group's capabilities
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Self-talk focusing on personal capabilities
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neutral statements (control condition)
Number of subjects: 80
Study: 19507642

Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis using direct current (3 mA, 10 min) (n: 10, 28 TrPs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Direct current only (n: 10, 30 TrPs)
Number of subjects: 20
Study: 17642435

Group type: EXPERIMENTAL
Intervention: Pharmacological treatments (ACE inhibitors, sartans, hypolipidemic drugs, drugs influencing proteinkinase C and vascular endothelial growth factor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antihyperglycemic therapy
Number of subjects: 0
Study: 15226779

Group type: EXPERIMENTAL
Intervention: High-dose neoadjuvant chemotherapy of epirubicin and cyclophosphamide
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ETAR-positive patients
Number of subjects: 44

Group type: COMPARATOR
Intervention: ETAR-negative patients
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ETAR as a predictive marker
Number of subjects: 44
Study: 12459619

Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish (EC40) applied every 6 months
Number of subjects: 238

Group type: COMPARATOR
Intervention: Neutral gel (control group)
Number of subjects: 238
Study: 9914578

Group type: EXPERIMENTAL
Intervention: Foley catheter insertion
Number of subjects: 149

Group type: COMPARATOR
Intervention: Intracervical prostaglandin E2 gel
Number of subjects: 149
Study: 7579505

Group type: EXPERIMENTAL
Intervention: CEA (Carcinoembryonic Antigen)
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: CA 15.3
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: Both CEA and CA 15.3
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: CEA (in ER+ patients)
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: CA 15.3 (in PgR+ patients)
Number of subjects: 1023

Group type: EXPERIMENTAL
Intervention: CEA and CA 15.3
Number of subjects: 1023
Study: 1962900

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Kabi 2165, Fragmin), started in the evening before surgery and then every evening
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Kabi 2165, Fragmin)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Conventional low-dose heparin
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Low molecular weight heparin (Kabi 2165, Fragmin) and Conventional low-dose heparin
Number of subjects: 1002
Study: 6764318

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate eye drops
Number of subjects: 374

Group type: COMPARATOR
Intervention: Betamethasone phosphate eye drops
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate with neomycin
Number of subjects: 374

Group type: COMPARATOR
Intervention: Betamethasone with neomycin
Number of subjects: 374

Group type: COMPARATOR
Intervention: Prednisolone eye drops
Number of subjects: 374

Group type: COMPARATOR
Intervention: Hydrocortisone eye drops
Number of subjects: 374
Study: 31937699

Group type: EXPERIMENTAL
Intervention: Community-initiated kangaroo mother care (KMC)
Number of subjects: 8402

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 8402
Study: 29391018

Group type: EXPERIMENTAL
Intervention: 8 weekly home visits from nursing students
Number of subjects: 98

Group type: COMPARATOR
Intervention: Wait-list control group (no intervention)
Number of subjects: 98
Study: 26804639

Group type: EXPERIMENTAL
Intervention: Buprenorphine Buccal Film (BBUP) 75 µg, 300 µg, 1200 µg (single-dose study)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Buprenorphine Buccal Film (BBUP) 60 µg, 120 µg, 180 µg, 240 µg BID (multiple-dose study)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Buprenorphine Buccal Film (BBUP)
Number of subjects: 35
Study: 24865870

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral coping skills training (CST)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Written emotional disclosure (WED)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control training
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 264
Study: 22723176

Group type: EXPERIMENTAL
Intervention: verbascoside (1 mg/dL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: verbascoside (2 mg/dL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: aspirin (100 μM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: verbascoside (1 and 2 mg/dL)
Number of subjects: 60
Study: 20105414

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (assessment-only)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Mandated students
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Voluntary students
Number of subjects: 84
Study: 17360767

Group type: EXPERIMENTAL
Intervention: Significant weight loss (>10 kg reduction)
Number of subjects: 6894

Group type: EXPERIMENTAL
Intervention: Significant weight gain (>10 kg increase)
Number of subjects: 6894

Group type: COMPARATOR
Intervention: Stable weight
Number of subjects: 6894
Study: 15723979

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Aliskiren 600 mg
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study: 11923041

Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) stimulation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Biventricular (BV) stimulation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Right ventricular (RV) stimulation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Atrioventricular (AV) delay optimization
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Shorter AV delay
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Responder subgroup
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nonresponder subgroup
Number of subjects: 39
Study: 9831693

Group type: EXPERIMENTAL
Intervention: d-aldosterone (12 pmol.min-1.kg-1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 5% dextrose (vehicle)
Number of subjects: 14
Study: 8305384

Group type: EXPERIMENTAL
Intervention: Doppler velocimetry revealed to clinician (study group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Doppler velocimetry not revealed to clinician (control group)
Number of subjects: 10
Study: 2525328

Group type: EXPERIMENTAL
Intervention: Nicorandil 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nicorandil 40 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nicorandil 60 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 8
Study: 30919004

Group type: EXPERIMENTAL
Intervention: Alcohol cue exposure in study 1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alcohol priming (0.6 g/kg body weight) in study 2
Number of subjects: 100

Group type: COMPARATOR
Intervention: Alcohol placebo beverage in study 2
Number of subjects: 100

Group type: COMPARATOR
Intervention: Water in study 2
Number of subjects: 100
Study: 28919097

Group type: EXPERIMENTAL
Intervention: Colonic j-pouch
Number of subjects: 74

Group type: COMPARATOR
Intervention: Side-to-end anastomosis
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both techniques (j-pouch and side-to-end anastomosis)
Number of subjects: 74
Study: 26420334

Group type: EXPERIMENTAL
Intervention: 100 μg Se-enriched yeast
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: 200 μg Se-enriched yeast
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: 300 μg Se-enriched yeast
Number of subjects: 491

Group type: COMPARATOR
Intervention: Matching placebo-yeast tablets
Number of subjects: 491
Study: 24281461

Group type: EXPERIMENTAL
Intervention: Thalidomide, 1.5 to 2.5 mg/kg per day for 8 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Thalidomide for nonresponders to placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 22026481

Group type: EXPERIMENTAL
Intervention: FV-guided surgery
Number of subjects: 400

Group type: COMPARATOR
Intervention: White light-guided surgery
Number of subjects: 400
Study: 18709483

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg t.i.d. for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17168490

Group type: EXPERIMENTAL
Intervention: Dynastat (new selective COX-2 inhibitor)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Profenid (conventional nonsteroidal anti-inflammatory drug)
Number of subjects: 180
Study: 14531871

Group type: EXPERIMENTAL
Intervention: Fragrance-containing solution (10 p.p.m. for 2 weeks, then 250 p.p.m. for 2 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both fragrance-containing and placebo solutions
Number of subjects: 15
Study: 11124551

Group type: EXPERIMENTAL
Intervention: J-pouch double tract reconstruction (PDT group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: rho-double tract reconstruction (RDT group)
Number of subjects: 40
Study: 9124837

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/day for 3 days)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Erythromycin (40 mg/kg/day for 10 days)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 85
Study: 8235261

Group type: EXPERIMENTAL
Intervention: EGb 761
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 3548368

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (gel only)
Number of subjects: 0
Study: 29515113

Group type: EXPERIMENTAL
Intervention: Peptide-based pseudosubstrates for cathepsin G
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27577549

Group type: EXPERIMENTAL
Intervention: LHB tenotomy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: LHB tenodesis
Number of subjects: 98
Study: 26324754

Group type: EXPERIMENTAL
Intervention: Ultrasound training
Number of subjects: 150

Group type: COMPARATOR
Intervention: Traditional physical examination instruction
Number of subjects: 150
Study: 23041960

Group type: EXPERIMENTAL
Intervention: 50% HRmax
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 70% HRmax
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 85% HRmax
Number of subjects: 10
Study: 22080777

Group type: EXPERIMENTAL
Intervention: Instant Recess® intervention (10-minute PA breaks introduced in classrooms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 8
Study: 19169930

Group type: EXPERIMENTAL
Intervention: Continuation of oxytocin until delivery
Number of subjects: 138

Group type: COMPARATOR
Intervention: Discontinuation of oxytocin at the onset of the active phase
Number of subjects: 138
Study: 16514097

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement therapy (CI therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group (physical fitness, cognitive, and relaxation exercises)
Number of subjects: 0
Study: 12721259

Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide 500 mg/m2 day 1, doxorubicin 40 mg/m2 day 1, and fluorouracil 200 mg/m2 intravenous bolus days 1 to 5)
Number of subjects: 242

Group type: COMPARATOR
Intervention: CAF plus LV (leucovorin 200 mg/m2 over 30 minutes days 1 to 5 given 1 hour before FU)
Number of subjects: 242

Group type: COMPARATOR
Intervention: CAF
Number of subjects: 242

Group type: COMPARATOR
Intervention: CAF plus LV
Number of subjects: 242
Study: 11175474

Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 441

Group type: COMPARATOR
Intervention: Optimal PTCA
Number of subjects: 441

Group type: COMPARATOR
Intervention: Non-optimal PTCA
Number of subjects: 441
Study: 9404405

Group type: EXPERIMENTAL
Intervention: L-arginine (L-arg, 625 mg/min x 10 min)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFX, 50 mg/min x 10 min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intracoronary isosorbide dinitrate
Number of subjects: 15
Study: 8371658

Group type: EXPERIMENTAL
Intervention: 500 ml of a 5% rice‐based liquid (L‐CHO)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 31-g food bar (S‐CHO)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (both L-CHO and S-CHO)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 500 ml of sweet placebo (CON)
Number of subjects: 6